A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: Dose-response curve slope strongly influences class-specific inhibitory potential

Journal of Virology

Volumn 86, Issue 20, 2012, Pages 11368-11372

  Deng, Kai ^a   Zink, M Christine ^b   Clements, Janice E ^b   Siliciano, Robert F ^a,c  

^a Department of Molecular and Comparative Pathobiology ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; L 870812; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFORMATION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84869003148     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01563-12     Document Type: Article

References (39)

1. Ambrose Z, et al. 2007. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J. Virol. 81:12145-12155.
2. Barouch DH, et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335-339.
3. Boyer JD, et al. 2006. Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response. J. Med. Primatol. 35:202-209.
4. Buck CB, et al. 2001. The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J. Virol. 75:181-191.
5. Chou TC. 1976. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59:253-276.
6. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
7. Chun TW, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
8. Chun TW, et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
9. Chun TW, Davey RT, Jr, Engel D, Lane HC, Fauci AS. 1999. Reemergence of HIV after stopping therapy. Nature 401:874-875.
10. Clavel F, Hance AJ. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
11. Daniel MD, et al. 1985. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201-1204.
12. Dinoso JB, et al. 2009. A simian immunodeficiency virus-infected ma-caque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83:9247-9257.
13. Domaoal RA, et al. 2008. Pre-steady-state kinetic studies establish entecavir 5=-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem. 283:5452-5459.
14. Finzi D, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
15. Garcia F, et al. 1999. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13:F79 -F86.
16. George MD, Reay E, Sankaran S, Dandekar S. 2005. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4_ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J. Virol. 79:2709-2719.
17. Gulick RM, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
18. Hammer SM, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:725-733.
19. Harrigan PR, Whaley M, Montaner JS. 1999. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13:F59 -F62.
20. Hel Z, et al. 2000. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6:1140-1146.
21. Hill AV. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40:iv-vii.
22. Iwata N, et al. 2007. Simian fetal brain progenitor cells for studying viral neuropathogenesis. J. Neurovirol. 13:11-22.
23. Jilek BL, et al. 2012. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18:446-451.
24. Lackner AA, Veazey RS. 2007. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu. Rev. Med. 58:461-476.
25. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
26. Lewis MG, et al. 2011. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 25:1347-1356.
27. North TW, et al. 2005. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J. Virol. 79:7349-7354.
28. North TW, et al. 2010. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84:2913-2922.
29. Perelson AS, et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
30. Pierson T, McArthur J, Siliciano RF. 2000. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18:665-708.
31. Shen A, et al. 2003. Resting CD4_ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77:4938-4949.
32. Shen L, et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766.
33. Siliciano JD, et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4_ T cells. Nat. Med. 9:727-728.
34. Van Rompay KK, et al. 1995. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob. Agents Chemother. 39:125-131.
35. Van Rompay KK, et al. 2004. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob. Agents Chemother. 48:1469-1487.
36. Veazey RS, et al. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198:1551-1562.
37. Wei X, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
38. Wong JK, et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
39. Zhang D, et al. 2003. Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J. Acquir. Immune. Defic. Syndr. 32:245-254.